Arvind Dasari
About
Arvind Dasari is a scholar working on Oncology, Epidemiology and Neurology.
According to data from OpenAlex, Arvind Dasari has authored 205 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 179 papers in Oncology, 78 papers in Epidemiology and 58 papers in Neurology. Recurrent topics in Arvind Dasari's work include Colorectal Cancer Treatments and Studies (78 papers), Neuroendocrine Tumor Research Advances (74 papers) and Lung Cancer Research Studies (62 papers). Arvind Dasari is often cited by papers focused on Colorectal Cancer Treatments and Studies (78 papers), Neuroendocrine Tumor Research Advances (74 papers) and Lung Cancer Research Studies (62 papers). Arvind Dasari collaborates with scholars based in United States, Spain and Italy. Arvind Dasari's co-authors include James C. Yao, Daniel M. Halperin, Chan Shen, Ya‐Chen Tina Shih, Shouhao Zhou, Ying Xu, Bo Zhao, Scott Kopetz, Satya Das and Michael J. Overman and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Arvind Dasari
192 papers receiving 7.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Arvind Dasari United States | 32 | 5.4k | 3.6k | 2.3k | 1.1k | 903 | 205 | 7.1k | ||
| Shouhao Zhou United States | 31 | 4.5k 0.8× | 2.8k 0.8× | 1.8k 0.8× | 1.1k 1.0× | 484 0.5× | 162 | 7.9k | ||
| Risto Sankila Finland | 50 | 3.7k 0.7× | 1.6k 0.4× | 1.3k 0.6× | 1.0k 0.9× | 2.3k 2.5× | 114 | 8.5k | ||
| Diane Reidy‐Lagunes United States | 38 | 4.3k 0.8× | 3.0k 0.8× | 2.1k 0.9× | 535 0.5× | 380 0.4× | 173 | 5.5k | ||
| Andrew Hendifar United States | 44 | 4.7k 0.9× | 1.4k 0.4× | 755 0.3× | 1.4k 1.3× | 490 0.5× | 275 | 6.8k | ||
| John K. Chan United States | 60 | 4.1k 0.8× | 1.6k 0.4× | 471 0.2× | 1.9k 1.7× | 1.4k 1.6× | 277 | 11.9k | ||
| Stephen V. Liu United States | 42 | 4.2k 0.8× | 1.1k 0.3× | 443 0.2× | 1.7k 1.6× | 806 0.9× | 341 | 6.9k | ||
| Alexandria T. Phan United States | 41 | 7.6k 1.4× | 7.7k 2.1× | 5.4k 2.4× | 863 0.8× | 183 0.2× | 139 | 10.8k | ||
| Michael Andersson Denmark | 37 | 3.2k 0.6× | 855 0.2× | 427 0.2× | 1000 0.9× | 1.6k 1.8× | 123 | 7.6k | ||
| M. Catherine Pietanza United States | 44 | 6.0k 1.1× | 1.9k 0.5× | 359 0.2× | 1.6k 1.5× | 297 0.3× | 121 | 7.5k | ||
| Steven G. DuBois United States | 47 | 2.0k 0.4× | 479 0.1× | 2.5k 1.1× | 2.4k 2.2× | 911 1.0× | 281 | 7.4k |
Countries citing papers authored by Arvind Dasari
Since
Specialization
Citations
This map shows the geographic impact of Arvind Dasari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arvind Dasari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arvind Dasari more than expected).
Fields of papers citing papers by Arvind Dasari
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Arvind Dasari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arvind Dasari. The network helps show where Arvind Dasari may publish in the future.
Co-authorship network of co-authors of Arvind Dasari
This figure shows the co-authorship network connecting the top 25 collaborators of Arvind Dasari. A scholar is included among the top collaborators of Arvind Dasari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arvind Dasari. Arvind Dasari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Dasari, Arvind, et al.. (2024). Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer: a plain language summary of the FRESCO-2 study. Future Oncology. 21(3). 281–292.
2.
Dasari, Arvind, et al.. (2024). Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy. Endocrine Related Cancer. 31(4).
3.
Bekaii‐Saab, Tanios, Arvind Dasari, Cathy Eng, et al.. (2024). Efficacy and safety of fruquintinib in patients with metastatic colorectal cancer according to prior treatment sequence in the refractory setting: Results from FRESCO and FRESCO-2.. Journal of Clinical Oncology. 42(16_suppl). 3579–3579.
4.
Baydogan, Seyda, Parul Agarwal, R. D. Wright, et al.. (2024). Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Cancer Prevention Research. 17(7). 335–342.
5.
Monlezun, Dominique, R. Patel, Dan Halperin, et al.. (2023). Artificial intelligence-augmented analysis of contemporary procedural, mortality, and cost trends in carcinoid heart disease in a large national cohort with a focus on the “forgotten pulmonic valve”. Frontiers in Cardiovascular Medicine. 9. 1071138–1071138.
6.
Das, Satya, Sharon Phillips, Rajiv Agarwal, et al.. (2023). Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours – A systematic review and meta-analysis. European Journal of Cancer. 182. 43–52.
7.
Thomas, Jane V., Kaysia Ludford, Jason Willis, et al.. (2023). Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination. Cancer Research Communications. 3(12). 2510–2517.
8.
Napolitano, Stefania, Aparna R. Parikh, Jason T. Henry, et al.. (2023). Novel Clinical Tool to Estimate Risk of False-Negative KRAS Mutations in Circulating Tumor DNA Testing. JCO Precision Oncology. 7(7). e2300228–e2300228.
9.
Rogers, Jane E., Hyunsoo Hwang, Wei Qiao, et al.. (2022). Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience. The Oncologist. 27(11). 952–957.
10.
Raghavan, Shreya, et al.. (2022). The Future of ctDNA-Defined Minimal Residual Disease: Personalizing Adjuvant Therapy in Colorectal Cancer. Clinical Colorectal Cancer. 21(2). 89–95.
11.
Ludford, Kaysia, Kanwal Raghav, Mariela A. Blum Murphy, et al.. (2021). Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.. Journal of Clinical Oncology. 39(15_suppl). 2520–2520.
12.
Eng, Cathy, Emerson Y. Chen, Jane E. Rogers, et al.. (2021). Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncology Practice. 17(10). 607–614.
13.
Rogers, Jane E., Michael Lam, Daniel M. Halperin, et al.. (2021). Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 112(1). 34–42.
14.
Unger, Joseph M., Dawn L. Hershman, Raymond U. Osarogiagbon, et al.. (2020). Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies. JNCI Cancer Spectrum. 4(4). pkaa034–pkaa034.
15.
Shen, Chan, Arvind Dasari, Ying Xu, et al.. (2018). Pre-existing Symptoms and Healthcare Utilization Prior to Diagnosis of Neuroendocrine Tumors: A SEER-Medicare Database Study. Scientific Reports. 8(1). 16863–16863.
16.
Parseghian, Christine M., Nila U. Parikh, Ji Yuan Wu, et al.. (2017). Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research. 23(15). 4146–4154.
17.
Loree, Jonathan M., Allan Andresson Lima Pereira, Michael Lam, et al.. (2017). Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. Clinical Cancer Research. 24(5). 1062–1072.
18.
Kopetz, Scott, Jayesh Desai, Emily Chan, et al.. (2015). Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer. Journal of Clinical Oncology. 33(34). 4032–4038.
19.
Messersmith, Wells A., Geoffrey I. Shapiro, James M. Cleary, et al.. (2014). A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014. Clinical Cancer Research. 21(1). 60–67.
20.
Arcaroli, John J., Kevin S. Quackenbush, Todd M. Pitts, et al.. (2012). Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib. Clinical Cancer Research. 18(9). 2704–2714.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Shouhao Zhou Breakdown of academic impact, for papers by Risto Sankila Breakdown of academic impact, for papers by Diane Reidy‐Lagunes Breakdown of academic impact, for papers by Andrew Hendifar Breakdown of academic impact, for papers by John K. Chan Breakdown of academic impact, for papers by Stephen V. Liu Breakdown of academic impact, for papers by Alexandria T. Phan Breakdown of academic impact, for papers by Michael Andersson Breakdown of academic impact, for papers by M. Catherine Pietanza Breakdown of academic impact, for papers by Steven G. DuBois